<SEC-DOCUMENT>0001104659-24-088680.txt : 20240813
<SEC-HEADER>0001104659-24-088680.hdr.sgml : 20240813
<ACCEPTANCE-DATETIME>20240813080530
ACCESSION NUMBER:		0001104659-24-088680
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		20
CONFORMED PERIOD OF REPORT:	20240813
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240813
DATE AS OF CHANGE:		20240813

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Theriva Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		241198860

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Synthetic Biologics, Inc.
		DATE OF NAME CHANGE:	20120305

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2421314d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:syn="http://syntheticbiologics.com/20240813">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_037_syn_syntheticbiologics.com_20240813 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20240813_20240813 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0000894158 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-08-13" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-08-13" id="Fact000004" name="dei:EntityCentralIndexKey">0000894158</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="syn-20240813.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-08-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-13</xbrli:startDate>
        <xbrli:endDate>2024-08-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_901_edei--DocumentType_c20240813__20240813_zHUfpE4pMVo2"><ix:nonNumeric contextRef="AsOf2024-08-13" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event
reported): <span id="xdx_90F_edei--DocumentPeriodEndDate_c20240813__20240813_zUgb2FTgeyv8"><ix:nonNumeric contextRef="AsOf2024-08-13" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">August 13, 2024</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90E_edei--EntityRegistrantName_c20240813__20240813_zRxl092HfmVl"><ix:nonNumeric contextRef="AsOf2024-08-13" id="Fact000011" name="dei:EntityRegistrantName">THERIVA BIOLOGICS, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 32%; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_902_edei--EntityIncorporationStateCountryCode_c20240813__20240813_zLYUnwiG104h"><ix:nonNumeric contextRef="AsOf2024-08-13" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="width: 1%; padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 34%; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_905_edei--EntityFileNumber_c20240813__20240813_zClMAD2wujf7"><ix:nonNumeric contextRef="AsOf2024-08-13" id="Fact000013" name="dei:EntityFileNumber">001-12584</ix:nonNumeric></span></b></span></td>
    <td style="width: 1%; padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 32%; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_907_edei--EntityTaxIdentificationNumber_c20240813__20240813_zMYG3isQsgXe"><ix:nonNumeric contextRef="AsOf2024-08-13" id="Fact000014" name="dei:EntityTaxIdentificationNumber">13-3808303</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation)</p></td>
    <td style="padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt">(Commission File No.)</span></td>
    <td style="padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="padding-right: 0.8pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer Identification</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">No.)</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90B_edei--EntityAddressAddressLine1_c20240813__20240813_zdNKPQfKUGf8"><ix:nonNumeric contextRef="AsOf2024-08-13" id="Fact000015" name="dei:EntityAddressAddressLine1">9605 Medical Center Drive</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressAddressLine2_c20240813__20240813_zlSq9G5QA7ac"><ix:nonNumeric contextRef="AsOf2024-08-13" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 270</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_904_edei--EntityAddressCityOrTown_c20240813__20240813_zxiGpaaCaoGj"><ix:nonNumeric contextRef="AsOf2024-08-13" id="Fact000017" name="dei:EntityAddressCityOrTown">Rockville</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressStateOrProvince_c20240813__20240813_zeDZ49jvCel2"><ix:nonNumeric contextRef="AsOf2024-08-13" format="ixt-sec:stateprovnameen" id="Fact000018" name="dei:EntityAddressStateOrProvince">Maryland</ix:nonNumeric></span> <span id="xdx_90C_edei--EntityAddressPostalZipCode_c20240813__20240813_zxbnfrgdIJJ2"><ix:nonNumeric contextRef="AsOf2024-08-13" id="Fact000019" name="dei:EntityAddressPostalZipCode">20850</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices and zip
code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_908_edei--CityAreaCode_c20240813__20240813_zOxMryHjpgtk"><ix:nonNumeric contextRef="AsOf2024-08-13" id="Fact000020" name="dei:CityAreaCode">301</ix:nonNumeric></span>) <span id="xdx_902_edei--LocalPhoneNumber_c20240813__20240813_zaMcdZVu7Bb3"><ix:nonNumeric contextRef="AsOf2024-08-13" id="Fact000021" name="dei:LocalPhoneNumber">417-4364</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 2%"><span style="font: 10pt Wingdings"><span id="xdx_90C_edei--WrittenCommunications_c20240813__20240813_zuTDDRTO6Ep1"><ix:nonNumeric contextRef="AsOf2024-08-13" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 2%"><span style="font: 10pt Wingdings"><span id="xdx_902_edei--SolicitingMaterial_c20240813__20240813_zypvVhOXJALb"><ix:nonNumeric contextRef="AsOf2024-08-13" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 2%"><span style="font: 10pt Wingdings"><span id="xdx_904_edei--PreCommencementTenderOffer_c20240813__20240813_zUiC6xiwXzCk"><ix:nonNumeric contextRef="AsOf2024-08-13" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 2%"><span style="font: 10pt Wingdings"><span id="xdx_906_edei--PreCommencementIssuerTenderOffer_c20240813__20240813_zpXvaJrNeKA6"><ix:nonNumeric contextRef="AsOf2024-08-13" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; width: 33%; padding-left: 6.4pt; text-align: center"><span style="font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 34%; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 33%; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Name of each exchange on which<br/>
 registered</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 6.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_904_edei--Security12bTitle_c20240813__20240813_zSwzTrcpmtVb"><ix:nonNumeric contextRef="AsOf2024-08-13" id="Fact000026" name="dei:Security12bTitle">Common stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_902_edei--TradingSymbol_c20240813__20240813_zVCNEU50hyaa"><ix:nonNumeric contextRef="AsOf2024-08-13" id="Fact000027" name="dei:TradingSymbol">TOVX</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_90E_edei--SecurityExchangeName_c20240813__20240813_zESH2BamWW9g"><ix:nonNumeric contextRef="AsOf2024-08-13" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">NYSE American</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company&#160;<span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_905_edei--EntityEmergingGrowthCompany_c20240813__20240813_zJeryHda1ZQ1"><ix:nonNumeric contextRef="AsOf2024-08-13" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by checkmark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-family: Wingdings"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding-right: 1.05pt; font-size: 10pt; text-align: justify; width: 1in"><b>Item 2.02.</b></td>
    <td style="padding-right: 1.05pt; font-size: 10pt; text-align: justify"><b>Results of Operations and Financial Condition.</b></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 13, 2024, Theriva Biologics, Inc., a
Nevada corporation (the &#8220;Registrant&#8221;) issued a press release that included financial information for its quarter ended June
30, 2024. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 8-K and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information in this Item 2.02 and in the press release attached
as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities
Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current
Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the
Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding-right: 1.05pt; font-size: 10pt; width: 1in"><b>Item 9.01.</b></td>
    <td style="padding-right: 1.05pt; font-size: 10pt; text-align: justify"><b>Financial Statements and Exhibits.</b></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 4%; padding-right: 0.8pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;</span></td>
    <td style="width: 96%; padding-right: 0.8pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit<br/>
Number</b></span></td>
    <td style="vertical-align: top; width: 3%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 87%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><a href="tm2421314d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm2421314d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release issued by
    Theriva Biologics, Inc., dated August 13, 2024</span></a></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.2pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: August 13,
    2024</span></td>
    <td colspan="3" style="padding-right: 2.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THERIVA BIOLOGICS, INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 52%; padding-right: 0.8pt">&#160;</td>
    <td style="width: 3%; padding-right: 0.8pt">&#160;</td>
    <td style="width: 5%; padding-right: 0.8pt">&#160;</td>
    <td style="width: 40%; padding-right: 0.8pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steven A. Shallcross</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven A. Shallcross</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjUEKwjAQRU/QOwxZS02j3XRpURGrSBFxG+0owTZTJrHqkbylsUUcBobh//e/ECOxpIWpkeE4KwvYY9PW2iOUeEFGe8bgyFfrDMIt8WqcZ219//7AnAKDgUljpU5B6K2dcVhlINNxko7VFOQkSyTsNiL66jnZi6nQeqNr0LaCHVPLBr3m15Cw10+y1Lz6qgOyM2QzSGI5yG9QMlGwpU4/iG8OiiIX0aifSCyZ7m1wzZ8e7ZeEeY1NqHMD/d/oAwQMSog= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2421314d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="tm2421314d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Theriva&#8482; Biologics Reports Second Quarter
2024 Operational Highlights and Financial Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>- VIRAGE, the Phase 2b clinical trial of VCN-01
in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma (PDAC), is expected to complete enrollment in the third
quarter of 2024-</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>- Received Fast Track Designation (FTD) Granted
by the U.S. Food and Drug Administration (FDA) for VCN-01 for the treatment of metastatic pancreatic adenocarcinoma- </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>- Received Rare Pediatric Disease Designation
(RPDD) Granted by the U.S. Food and Drug Administration (FDA) for VCN-01 for the treatment of children with retinoblastoma- </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>- As of June 30, 2024, Theriva Biologics reports
$16.6 million in cash, which is expected to provide runway into the second quarter of 2025-</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rockville, MD, August 13, 2024 </B>&#8211;
Theriva&#8482; Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer
and related diseases in areas of high unmet need, today reported financial results for the second quarter ended June 30, 2024, and provided
a corporate update.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8220;We remain on track to complete enrollment for VIRAGE, our Phase
2b trial in metastatic PDAC during the third quarter and are pleased with the FDA&#8217;s decision to grant FTD to VCN-01, highlighting
the urgent need for new options to treat this deadly disease,&#8221; said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics.
 &#8220;Our lead oncolytic virus (OV) product candidate, VCN-01 is uniquely designed for co-administration with chemotherapy and/or immunotherapy
to enhance tumor access by these agents and elicit a persistent antitumor immune response. The ongoing VIRAGE trial is evaluating VCN-01
in combination with standard-of-care chemotherapy, gemcitabine/nab-paclitaxel, as a first line therapy to enable the earliest possible
use in metastatic PDAC. We look forward to building upon the compelling clinical data from Phase 1 studies that underscores VCN-01&#8217;s
multiple modes of action and potential to overcome historical challenges around systemic OV administration. Beyond PDAC, we continue to
pursue opportunities that maximize the therapeutic potential of VCN-01. To that end, we are excited by the grant of RPDD to VCN-01 for
the treatment of children with retinoblastoma. We will continue to build a portfolio of potentially improved therapeutic combinations
as part of our broader strategy to address unmet needs for difficult to treat cancers. Additionally, we have taken steps to further rationalized
our burn, which will allow us to extend our cash runway by an additional quarter and bring us closer to the completion and data readout
of the VIRAGE trial.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Recent Program Highlights and Anticipated
Milestones:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>VCN-01:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B>Pancreatic Ductal Adenocarcinoma (PDAC):</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Dosing is underway and enrollment is nearing completion for VIRAGE, the randomized, controlled, multicenter, open-label Phase 2b trial
of VCN-01 in combination with standard-of-care chemotherapy (gemcitabine/nab-paclitaxel) as a first line therapy in newly diagnosed metastatic
PDAC patients. The trial intends to enroll 92 evaluable patients across sites in the U.S. and Spain, and is expected to complete enrollment
in the third quarter of 2024.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="tm2421314d1_ex99-1img002.jpg" ALT="">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">The U.S. FDA granted FTD to lead clinical candidate VCN-01 in combination with gemcitabine and nab-paclitaxel to improve progression-free
survival and overall survival in patients with metastatic pancreatic adenocarcinoma. Overall survival and progression free survival are
the primary and key secondary endpoints respectively in the ongoing VIRAGE study. Both the FDA and EMA previously granted orphan drug
designation to VCN-01 for treatment of PDAC.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B>Retinoblastoma:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Results from the investigator sponsored Phase 1 trial evaluating the safety and activity of intravitreal VCN-01 in pediatric patients
with refractory retinoblastoma were determined to be positive by the study Monitoring Committee. Discussions with key opinion leaders
worldwide, as well as with regulatory agencies, are ongoing to refine our retinoblastoma clinical strategy.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">The U.S. FDA granted RPDD to lead clinical candidate VCN-01 to treat pediatric patients with retinoblastoma. The FDA has previously
granted orphan drug designation to VCN-01 in this indication.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If a Biologics License Application for VCN-01 for the treatment of retinoblastoma
is ultimately approved by the FDA, Theriva may be eligible to receive a Priority Review Voucher that can be redeemed to receive a priority
review for any subsequent marketing application, or may be sold or transferred. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>SYN-004 (ribaxamase)</I>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dosing and safety follow-up were completed for the second cohort of the Phase
1b/2a randomized, double-blinded, placebo-controlled clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant
(HCT) recipients for the prevention of acute graft-versus-host-disease (aGVHD). </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
the Data Safety and Monitoring Committee recommends continuation of the trial, enrollment into the third cohort could commence in the
second half of 2024 contingent on adequate funding.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Second Quarter Ended June 30, 2024 Financial Results</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses decreased
to $1.5 million for the three months ended June 30, 2024, from $2.7 million for the three months ended June 30, 2023. This decrease of
45% is primarily comprised of the decrease in employee compensation costs, consulting fees, audit fees, lower director and officer insurance,
and a decrease in fair value of the contingent consideration adjustment, offset by increased investor relation costs. The charge related
to stock-based compensation expense was $114,000 for the three months ended June 30, 2024, compared to $106,000 for the three months ended
June 30, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses decreased
to $3.0 million for the three months ended June 30, 2024, from approximately $3.1 million for the three months ended June 30, 2023.
This decrease of 6% is primarily the result of lower clinical trial expenses related to our VIRAGE Phase 2 clinical trial of VCN-01
in PDAC and lower expenses related to our Phase 1a clinical trial of SYN-020 which has completed, offset by increased expenses to
our Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic HCT recipients. We anticipate research and development expense
to increase as we continue enrollment in our VIRAGE Phase 2 clinical trial of VCN-01 in PDAC, advance our VCN-01 program in
retinoblastoma, expand GMP manufacturing activities for VCN-01, and continue supporting our other preclinical and discovery
initiatives. The charge related to stock-based compensation expense was $58,000 for the three months ended June 30, 2024, compared
to $40,000 related to stock-based compensation expense for the three months ended June 30, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="tm2421314d1_ex99-1img003.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the quarter ended June 30, 2024, we experienced
a sustained decline in the quoted market price of our common stock and we deemed this to be a triggering event for impairment. The Company
performed an interim impairment analysis using the &#8220;Income approach&#8221; that requires significant judgments, including primarily
the estimation of future development costs, the probability of success in various phases of its development programs, potential post-launch
cash flows and a risk-adjusted weighted average cost of capital. We concluded that the IPR&amp;D was not impaired as of June 30, 2024,
however, goodwill with a carrying value of $5.5 million was written down to its estimated fair value of $1.5 million and an impairment
charge of $4.0 million was recorded during the quarter ended June 30, 2024. The decrease in the valuation was primarily driven by an increase
in the discount rate which was impacted by an increase in the company specific risk premium, and not by material changes to the clinical
and administrative operations of the business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-style: normal">Other
income was $172,000 for the three months ended June 30, 2024 compared to other income of $377,000 for the three months ended June 30,
2023. Other income for the three months ended June 30, 2024 is primarily comprised of interest income of $173,000 and an exchange loss
of $1,000. Other income for the three months ended June 30, 2023 is primarily comprised of interest income of $381,000 and exchange loss
of $4,000.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cash and cash equivalents totaled $16.6 million as of June 30, 2024,
compared to $23.2 million as of December 31, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Theriva&#8482; Biologics,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Theriva&#8482; Biologics (NYSE American: TOVX),
is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet
need. The Company is advancing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery
to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor
response by the patient&#8217;s immune system. The Company&#8217;s lead candidates are: (1) VCN-01, an oncolytic adenovirus designed
to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical
and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam
antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms
such as VRE (vancomycin resistant Enterococci) and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in
allogeneic hematopoietic cell transplant (HCT) recipients; and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline
phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please
visit Theriva Biologics&#8217; website at&nbsp;<U>www.therivabio.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2421314d1_ex99-1img004.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><I>This release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified
by terminology such as &ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;potential,&rdquo; &ldquo;continue,&rdquo; &ldquo;expects,&rdquo;
 &ldquo;anticipates,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; and similar expressions,
and include statements regarding remaining on track to complete enrollment for VIRAGE Phase 2b trial of VCN-01 in combination with chemotherapy for metastatic PDAC during the third
quarter; VCN-01 being uniquely designed for co-administration with chemotherapy and/or immunotherapy to enhance tumor access and elicit
a persistent antitumor immune response; the cash providing runway into the second quarter of 2025, building upon the clinical data from
Phase 1 studies that underscores VCN-01&rsquo;s multiple modes of action; the potential to overcome historical challenges around systemic
OV administration, continuing to pursue opportunities that maximize the therapeutic potential of VCN-01; continuing to build a portfolio
of potentially improved therapeutic combinations as part of the Company&rsquo;s broader strategy to address unmet needs for difficult
to treat cancers; further rationalized burn, which will allow the Company to extend its cash runway by an additional quarter and bring
it closer to the completion and data readout of the VIRAGE trial , the PDAC trial enrolling 92 evaluable patients across sites in the
U.S. and Spain, and completion of enrollment in the third quarter of 2024; the Company being eligible to receive a Priority Review Voucher:
and, enrollment into the third cohort commencing in the second half of 2024 contingent on adequate funding. Important factors that could
cause actual results to differ materially from current expectations include, among others, the Company&rsquo;s and VCN&rsquo;s ability
to reach clinical milestones when anticipated, including the ability to continue to enroll patients as planned and the completion of
enrollment in VIRAGE in the third quarter of 2024, generating clinical data that establishes VCN-01 may lead to improved clinical outcomes
for patients with PDAC and other solid cancers; the Company&rsquo;s and VCN&rsquo;s product candidates demonstrating safety and effectiveness,
as well as results that are consistent with prior results; the ability to complete clinical trials on time and achieve the desired results
and benefits; the ability to obtain regulatory approval for commercialization of product candidates or to comply with ongoing regulatory
requirements, regulatory limitations relating to the Company&rsquo;s and VCN&rsquo;s ability to promote or commercialize their product
candidates for the specific indications, acceptance of product candidates in the marketplace and the successful development, marketing
or sale of the Company&rsquo;s and VCN&rsquo;s products, developments by competitors that render such products obsolete or non-competitive,
the Company&rsquo;s and VCN&rsquo;s ability to maintain license agreements, the continued maintenance and growth of the Company&rsquo;s
and VCN&rsquo;s patent estate, the ability to continue to remain well financed and the cash providing a runway into the second quarter
of 2025, and other factors described in the Company&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2023 and its other
filings with the SEC, including subsequent periodic reports on Forms 10-Q and current reports on Form 8-K. The information in this release
is provided only as of the date of this release, and Theriva Biologics undertakes no obligation to update any forward-looking statements
contained in this release on account of new information, future events, or otherwise, except as required by law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For further information, please contact:</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Relations:</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chris Calabrese&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LifeSci Advisors, LLC&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ccalabrese@lifesciadvisors.com&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">917-680-5608</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2421314d1_ex99-1img006.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Theriva Biologics,&nbsp;Inc. and Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Balance Sheets</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(In thousands except share and par value amounts)</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><B>June 30,
    2024</B></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><B>December&nbsp;31,&nbsp;2023</B></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: -0.1in; padding-left: 0.1in"><B>Assets</B></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in"><B>Current Assets</B></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Cash and cash equivalents</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">16,593</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">23,177</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Tax credit receivable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,759</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,812</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 13.2pt">Prepaid expenses and other current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,363</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,414</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 19.2pt"><B>Total Current
    Assets</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><B>19,715</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><B>27,403</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in"><B>Non-Current Assets</B></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Property and equipment, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">336</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">422</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Restricted cash</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">99</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">102</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Right of use asset</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,519</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,759</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">In-process research and development</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">19,179</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">19,755</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.1in; padding-left: 0.1in">Goodwill</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,465</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,700</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Deposits and other assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">77</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">78</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in"><B>Total
    Assets</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><B>$</B></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><B>42,390</B></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><B>$</B></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><B>55,219</B></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: -0.1in; padding-left: 0.1in"><B>Liabilities
    and Stockholders&lsquo; Equity</B></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in"><B>Current Liabilities:</B></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Accounts payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">935</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">770</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Accrued expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,489</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,995</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Accrued employee benefits</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">969</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,517</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Deferred research and development tax credit-current portion</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">880</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">906</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Loans payable-current</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">62</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">63</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 13.2pt">Operating lease liability-current portion</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">513</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">487</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 19.2pt"><B>Total Current
    Liabilities</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><B>6,848</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><B>6,738</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in"><B>Non-current Liabilities</B></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Non-current contingent consideration</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,201</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,274</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Loan Payable - non-current</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">93</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">162</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Non-current deferred research and development tax credit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">440</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">906</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 13.2pt">Non-current operating lease liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,162</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,442</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 13.2pt"><B>Total Liabilities</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><B>14,744</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><B>15,522</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in"><B>Commitments and
    Contingencies (Note 13)</B></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Temporary Equity; 10,000,000 authorized</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Series C convertible preferred stock, $0.001 par value; 275,000 issued and 139,569 outstanding</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,018</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,006</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Series D convertible preferred stock, $0.001 par value; 100,000 issued and outstanding</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">728</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">728</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in"><B>Stockholders&rsquo;
    Equity:</B></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Common stock, $0.001 par value; 350,000,000 shares authorized, 23,113,391 issued and 22,393,158 outstanding at June 30, 2024 and 17,868,282 issued and 17,148,049 outstanding at December 31, 2023</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">23</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">18</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Additional paid-in capital</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">349,673</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">346,519</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Treasury stock at cost, 720,233 shares at June 30, 2024 and at December 31, 2023</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(288</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(288</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Accumulated other comprehensive (loss) income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(709</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">32</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 13.2pt">Accumulated deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(322,799</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(309,318</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in"><B>Total
    Stockholders&rsquo; Equity</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><B>25,900</B></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><B>36,963</B></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in"><B>Total
    Liabilities and Stockholders&rsquo; Equity</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><B>$</B></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><B>42,390</B></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><B>$</B></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><B>55,219</B></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><IMG SRC="tm2421314d1_ex99-1img007.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Theriva Biologics,&nbsp;Inc. and Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Statements of Operations and Comprehensive
Loss</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(In thousands, except share and per share amounts)</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the three months ended June 30,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the six months ended June 30,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Operating Costs and Expenses:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">General and administrative</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1,467</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">2,687</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">3,401</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">4,888</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Research and development</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,953</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,133</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,412</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,110</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 13.2pt">Goodwill impairment</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,068</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,068</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 19.2pt">Total Operating Costs and Expenses</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">8,488</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">5,820</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">13,881</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">10,998</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Loss from Operations</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(8,488</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(5,820</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(13,881</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(10,998</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Other Income/Expense:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Foreign currency exchange (loss) gain</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(4</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 13.2pt">Interest income</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">173</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">381</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">402</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">745</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 19.2pt">Total Other Income</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">172</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">377</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">400</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">746</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Net Loss</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(8,316</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(5,443</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(13,481</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(10,252</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Income tax benefit</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">359</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">689</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">Net Loss Attributable to Common Stockholders</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(8,316</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(5,084</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(13,481</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(9,563</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Net Loss Per Share - Basic and Dilutive</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(0.43</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(0.34</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(0.74</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(0.63</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Weighted average number of shares outstanding during the period - Basic and Dilutive</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">19,393,401</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">15,166,209</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">18,270,725</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">15,145,252</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Net Loss</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(8,316</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(5,084</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(13,481</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(9,563</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">(Loss) gain on foreign currency translation</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(172</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(51</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(741</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">323</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">Total comprehensive loss</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(8,488</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(5,135</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(14,222</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(9,240</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>syn-20240813.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaqPmbOdzZR+WYkxtmB4bak6ryQkPS7WuS1si/zGUV8H -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:syn="http://syntheticbiologics.com/20240813" elementFormDefault="qualified" targetNamespace="http://syntheticbiologics.com/20240813">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://syntheticbiologics.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="syn-20240813_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="syn-20240813_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>syn-20240813_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>syn-20240813_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://syntheticbiologics.com/role/Cover" xlink:href="syn-20240813.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://syntheticbiologics.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm2421314d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2421314d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  ^ -X# 2(  A$! Q$!_\0
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M<+]0Q4GF&8RIY93Y$WB:6-<J49.5/F<X)*C5_>.Z2E=+6Z_3G]CGXZ_\%&O
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MT[5;.S\5WEE)-IUO<:QH4OAZ[MY8H_.+>0MT;N"Y=H;4& QW$\2R(X_.A/\
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MY5:Z?8B'<Z9E5<HNXG*L<?[(XSN[$"K-1RQ^: -[IA@V8RH)P"-IW*PVG/.
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M>4\KQ&$AA<-PQ1P$Y<V29?6E*I'%87$4IJ#J8>.'HJ&'I<]&=9\Y\YPYX?\
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=\48BO6IPQ/\ ;&!SS$XC(,MG3PZX7I8:$ZL3_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2421314d1_ex99-1img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2421314d1_ex99-1img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ^ -X# 2(  A$! Q$!_\0
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M?F8Q_CLZV?\ U$G^Z?Y5\O:#K5SX?UB/4;.-7N$5U0,"0-PQG ZX!KZBN/\
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M5*7+RQU??^OT.["4\3*:J5':/1?U^I8I&Z4M!KS3V#QWXWG,VA_2?_V2NO\
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M-G8<9SUQ^%:>I7#2>&Q*"P+(C;^AZJ<U+_PC5AG;F?RB<^5YIV?E5Z33H);
M63;O)"A<9YP,8_E3E.#MZBC1J+F5K)I??_P?O,_5V9VL;5F98)Y=LA!QD $@
M9[9Q1_9]M8WUO):SK;%W(:(DD3 ]L$]1ZUHW5A!>6Y@F!*'' .",="#5:TT6
MUM9Q.&FEE4;5::0N5'MFI4E;<N5*7/>RMI\OZ_X<S=4A>74MY@-_"(P#;I+M
M:,Y^]COFK^@2Q2Z?F)IM@=@%F^\G/3Z5)>:1;74PN"TL4P7;YD+E21Z'%6+&
GP@L(!% "%Y)+'))/4DT2G%T[==/Z_KYA"E-5N9[:_P!=_OT['__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm2421314d1_ex99-1img003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2421314d1_ex99-1img003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ^ -X# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#WXGBL77O%
M.E>'+4S:A=(C?P1*<NY]A7"?$OQ[J6CZA_8VFA8&,:N]R.6YSPOI7$Z%X)U[
MQ;-)?W,CP6[?,]W>9_>?3^]_+BN^C@UR*K5E9,YYU=>6.YV]A\:+674WCO=-
MD@LV(\N1#N91ZL/\/UKTFSU"VU*W2XLKB*>%QD21MN'Z5Y5/\/\ PM?60TS3
M]0,.H0];J0AEG)_V<XQ],?C7'W-MXH^'>JL%DDMPQ'[R+)AFQ]0 ?QY%;2PM
M*J[4WROL^IE"O+5O5>1ZSXC^(<&BWK6<%HT\R$;V?Y$'T/4_RK:T'Q7IWB"#
M=!*(Y@<-!(<,/\17#:9XY\.>,XX]/\0V4=K>;<+.6 0G_9?JI]CQ6/XB\'WG
MAS&HVMP)K,$%)HSADSTS_B.*CZM"WLYKEG^8W5DO>3YE^1[;DYHS]*XCX;:[
MJ&LZ;="^F,OD,JQLP&[!!ZXZURGBS4_'D'BB^CTH:E]B#@1>5;;EQCL=M<T<
M,W4=-R2L;NHN52L>Q9^E&?3%?.]]XO\ 'FF%/M]Y?VWF9V>= $W8ZXRON*FM
M?$?Q$OH%GM9M3GA;I)%:AE///.VNC^SI6YN=6^9G]878^@2<#M2@\GI7FGP_
MO_%MU>7X\0?;EB6WW1&>#8-^1T.!V[5SWP]\7Z]JWC2TLK[4I9[=UD+1L!@X
M0D=JP>$DN9W3Y33VJT5MSVW/-+4>X]J<"?:N2Z-1U%-)-)N)Z4P'T4S=2[N<
M9%*Z>P#J0YQQ29XI"W%# 7-*.M>6:C=^./\ A90M[7S_ .SO.7;\G[GRL G)
MQUZUZB":UJ4N2VM[D1ES-^0^BD!/M1FLKEBT4W-&X\47 =13=QSTI1G-"8'@
M'Q= 'C=B.OV://ZUW/B!Y(OA]H1C8J=D6?\ OV:Z[7/"VC^(H?+U*T21L860
M##K]#6'XQL8K3PS86<6XQP.L:[CDX"$"O5HXA3=*%OA/,Q<'"E4EW1E^#-+M
M]5MYKJ\RPA<*J D#\16A+XKL;^];2[BP273Y3Y.&YSVZ4[P05M=&U"5@2L;E
MR!U("UE-K_@R-_[5C29[C=N%M@Y##N1TKDQT,34KM4]D_N,</#EH0=.ROO<J
M:M\&[2XU"&33+PVUHQ_>Q2C>5'^R>_T/YTOB2[T/0O"4OA>PN99YE*9W-OVX
M8'D]NG05A:WXYU?62T2RFVM6_P"64&02.G)ZFKWA_P"'FHZH\<^H'[):L-V#
M_K''L,<?C7H<LHP4\1+;;^NIU<RD^6G'<W_A.,6.H\$?O$[>QQ7H?I6=HN@Z
M?H-LT%A$45SEV9B2Q]36D1SFO+Q$U4J.2ZG73BXQL>/_ !O&)=#Q_=G_ /9*
MZ[X6C_B@;'_>D_\ 0S7)?'#_ %NB?[L__LE=;\+1_P 4%8_[TG_H9KMJ6^I1
M?F8Q_CLZV?\ U$G^Z?Y5\O:#K5SX?UB/4;.-7N$5U0,"0-PQG ZX!KZBN/\
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M5*7+RQU??^OT.["4\3*:J5':/1?U^I8I&Z4M!KS3V#QWXWG,VA_2?_V2NO\
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M-G8<9SUQ^%:>I7#2>&Q*"P+(C;^AZJ<U+_PC5AG;F?RB<^5YIV?E5Z33H);
M63;O)"A<9YP,8_E3E.#MZBC1J+F5K)I??_P?O,_5V9VL;5F98)Y=LA!QD $@
M9[9Q1_9]M8WUO):SK;%W(:(DD3 ]L$]1ZUHW5A!>6Y@F!*'' .",="#5:TT6
MUM9Q.&FEE4;5::0N5'MFI4E;<N5*7/>RMI\OZ_X<S=4A>74MY@-_"(P#;I+M
M:,Y^]COFK^@2Q2Z?F)IM@=@%F^\G/3Z5)>:1;74PN"TL4P7;YD+E21Z'%6+&
GP@L(!% "%Y)+'))/4DT2G%T[==/Z_KYA"E-5N9[:_P!=_OT['__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tm2421314d1_ex99-1img004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2421314d1_ex99-1img004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ^ -X# 2(  A$! Q$!_\0
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M?F8Q_CLZV?\ U$G^Z?Y5\O:#K5SX?UB/4;.-7N$5U0,"0-PQG ZX!KZBN/\
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M5*7+RQU??^OT.["4\3*:J5':/1?U^I8I&Z4M!KS3V#QWXWG,VA_2?_V2NO\
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M-G8<9SUQ^%:>I7#2>&Q*"P+(C;^AZJ<U+_PC5AG;F?RB<^5YIV?E5Z33H);
M63;O)"A<9YP,8_E3E.#MZBC1J+F5K)I??_P?O,_5V9VL;5F98)Y=LA!QD $@
M9[9Q1_9]M8WUO):SK;%W(:(DD3 ]L$]1ZUHW5A!>6Y@F!*'' .",="#5:TT6
MUM9Q.&FEE4;5::0N5'MFI4E;<N5*7/>RMI\OZ_X<S=4A>74MY@-_"(P#;I+M
M:,Y^]COFK^@2Q2Z?F)IM@=@%F^\G/3Z5)>:1;74PN"TL4P7;YD+E21Z'%6+&
GP@L(!% "%Y)+'))/4DT2G%T[==/Z_KYA"E-5N9[:_P!=_OT['__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tm2421314d1_ex99-1img006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2421314d1_ex99-1img006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ^ -X# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#WXGBL77O%
M.E>'+4S:A=(C?P1*<NY]A7"?$OQ[J6CZA_8VFA8&,:N]R.6YSPOI7$Z%X)U[
MQ;-)?W,CP6[?,]W>9_>?3^]_+BN^C@UR*K5E9,YYU=>6.YV]A\:+674WCO=-
MD@LV(\N1#N91ZL/\/UKTFSU"VU*W2XLKB*>%QD21MN'Z5Y5/\/\ PM?60TS3
M]0,.H0];J0AEG)_V<XQ],?C7'W-MXH^'>JL%DDMPQ'[R+)AFQ]0 ?QY%;2PM
M*J[4WROL^IE"O+5O5>1ZSXC^(<&BWK6<%HT\R$;V?Y$'T/4_RK:T'Q7IWB"#
M=!*(Y@<-!(<,/\17#:9XY\.>,XX]/\0V4=K>;<+.6 0G_9?JI]CQ6/XB\'WG
MAS&HVMP)K,$%)HSADSTS_B.*CZM"WLYKEG^8W5DO>3YE^1[;DYHS]*XCX;:[
MJ&LZ;="^F,OD,JQLP&[!!ZXZURGBS4_'D'BB^CTH:E]B#@1>5;;EQCL=M<T<
M,W4=-R2L;NHN52L>Q9^E&?3%?.]]XO\ 'FF%/M]Y?VWF9V>= $W8ZXRON*FM
M?$?Q$OH%GM9M3GA;I)%:AE///.VNC^SI6YN=6^9G]878^@2<#M2@\GI7FGP_
MO_%MU>7X\0?;EB6WW1&>#8-^1T.!V[5SWP]\7Z]JWC2TLK[4I9[=UD+1L!@X
M0D=JP>$DN9W3Y33VJT5MSVW/-+4>X]J<"?:N2Z-1U%-)-)N)Z4P'T4S=2[N<
M9%*Z>P#J0YQQ29XI"W%# 7-*.M>6:C=^./\ A90M[7S_ .SO.7;\G[GRL G)
MQUZUZB":UJ4N2VM[D1ES-^0^BD!/M1FLKEBT4W-&X\47 =13=QSTI1G-"8'@
M'Q= 'C=B.OV://ZUW/B!Y(OA]H1C8J=D6?\ OV:Z[7/"VC^(H?+U*T21L860
M##K]#6'XQL8K3PS86<6XQP.L:[CDX"$"O5HXA3=*%OA/,Q<'"E4EW1E^#-+M
M]5MYKJ\RPA<*J D#\16A+XKL;^];2[BP273Y3Y.&YSVZ4[P05M=&U"5@2L;E
MR!U("UE-K_@R-_[5C29[C=N%M@Y##N1TKDQT,34KM4]D_N,</#EH0=.ROO<J
M:M\&[2XU"&33+PVUHQ_>Q2C>5'^R>_T/YTOB2[T/0O"4OA>PN99YE*9W-OVX
M8'D]NG05A:WXYU?62T2RFVM6_P"64&02.G)ZFKWA_P"'FHZH\<^H'[):L-V#
M_K''L,<?C7H<LHP4\1+;;^NIU<RD^6G'<W_A.,6.H\$?O$[>QQ7H?I6=HN@Z
M?H-LT%A$45SEV9B2Q]36D1SFO+Q$U4J.2ZG73BXQL>/_ !O&)=#Q_=G_ /9*
MZ[X6C_B@;'_>D_\ 0S7)?'#_ %NB?[L__LE=;\+1_P 4%8_[TG_H9KMJ6^I1
M?F8Q_CLZV?\ U$G^Z?Y5\O:#K5SX?UB/4;.-7N$5U0,"0-PQG ZX!KZBN/\
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M5*7+RQU??^OT.["4\3*:J5':/1?U^I8I&Z4M!KS3V#QWXWG,VA_2?_V2NO\
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M-G8<9SUQ^%:>I7#2>&Q*"P+(C;^AZJ<U+_PC5AG;F?RB<^5YIV?E5Z33H);
M63;O)"A<9YP,8_E3E.#MZBC1J+F5K)I??_P?O,_5V9VL;5F98)Y=LA!QD $@
M9[9Q1_9]M8WUO):SK;%W(:(DD3 ]L$]1ZUHW5A!>6Y@F!*'' .",="#5:TT6
MUM9Q.&FEE4;5::0N5'MFI4E;<N5*7/>RMI\OZ_X<S=4A>74MY@-_"(P#;I+M
M:,Y^]COFK^@2Q2Z?F)IM@=@%F^\G/3Z5)>:1;74PN"TL4P7;YD+E21Z'%6+&
GP@L(!% "%Y)+'))/4DT2G%T[==/Z_KYA"E-5N9[:_P!=_OT['__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tm2421314d1_ex99-1img007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2421314d1_ex99-1img007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ^ -X# 2(  A$! Q$!_\0
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M?F8Q_CLZV?\ U$G^Z?Y5\O:#K5SX?UB/4;.-7N$5U0,"0-PQG ZX!KZBN/\
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M5*7+RQU??^OT.["4\3*:J5':/1?U^I8I&Z4M!KS3V#QWXWG,VA_2?_V2NO\
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M-G8<9SUQ^%:>I7#2>&Q*"P+(C;^AZJ<U+_PC5AG;F?RB<^5YIV?E5Z33H);
M63;O)"A<9YP,8_E3E.#MZBC1J+F5K)I??_P?O,_5V9VL;5F98)Y=LA!QD $@
M9[9Q1_9]M8WUO):SK;%W(:(DD3 ]L$]1ZUHW5A!>6Y@F!*'' .",="#5:TT6
MUM9Q.&FEE4;5::0N5'MFI4E;<N5*7/>RMI\OZ_X<S=4A>74MY@-_"(P#;I+M
M:,Y^]COFK^@2Q2Z?F)IM@=@%F^\G/3Z5)>:1;74PN"TL4P7;YD+E21Z'%6+&
GP@L(!% "%Y)+'))/4DT2G%T[==/Z_KYA"E-5N9[:_P!=_OT['__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140166633773952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 13, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 13,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">THERIVA BIOLOGICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000894158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3808303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9605 Medical Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">417-4364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TOVX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M> \^>Q\ETWLJ.?]74_P$4$L#!!0    ( *Y #5F7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ KD -6:K$(A8S 0
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M6N=6RKV'5[+E&''\GN4/4$L#!!0    ( *Y #5DD'INBK0   /@!   :
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=
M6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\
MI%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*<//Y#='7=:7PX_;(X
M\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P6B#BR2!M:59]L$].
MM.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " "N0 U999!YDAD!  #/ P
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M<' N>&UL4$L! A0#%     @ KD -69<!6^?O    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ KD -69E<G",0
M!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " "N0 U9N=-2<F<$   I$0  &               @($."
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ KD -69^@&_"Q
M @  X@P   T              ( !JPP  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M    " "N0 U9EXJ[',     3 @  "P              @ &'#P  7W)E;',O
M+G)E;'-02P$"% ,4    " "N0 U9JL0B%C,!   B @  #P
M@ %P$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ KD -620>FZ*M
M^ $  !H              ( !T!$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ KD -6660>9(9 0  SP,  !,              ( !
MM1(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  _Q,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2421314d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://syntheticbiologics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>syn-20240813.xsd</File>
    <File>syn-20240813_lab.xml</File>
    <File>syn-20240813_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2421314d1_8k.htm">tm2421314d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>20
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2421314d1_8k.htm": {
   "nsprefix": "syn",
   "nsuri": "http://syntheticbiologics.com/20240813",
   "dts": {
    "schema": {
     "local": [
      "syn-20240813.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "syn-20240813_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "syn-20240813_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2421314d1_8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://syntheticbiologics.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-08-13",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2421314d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-08-13",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2421314d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>21
<FILENAME>0001104659-24-088680-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-24-088680-xbrl.zip
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M #5Y2-3SX#V4@'JWL/38;C(#B -"I]LA0) (0LTHGR M:,3X,ZL][C!G6S$
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M@%;R&;&R"O2[K 05M=A^O[R^Z4I\$IOU)O'7"F=$;/DO4$L#!!0    ( *Y
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M(D!Q:'Q0WR@$QE 1IHO.D:X;>\"]LK;XQOURKV6U1_X'4$L#!!0    ( *Y
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MJ]0JY6JYYI3_5_QLM0IEZ75+I7+QW_WN#CNYO/VP,]&*3WUE4EPF!X?%X*N
MARRF;.%'(B!,W/;@VW?\]_]S4#NH'+*/4KFJ*^V078N^"J(05K.5[[#_B7D
MSVQO54J5&OO6%P&/I/*YR_X M+N(^I!Q^.(GZ7/?EO"':Q'&;A2.Q^^\SY'@
M:_%[71P7V/>+ZY//YQ:+>H)=]7@H6*7-;%?ZTH:#1P$>7W78]].OA5)Y>TOZ
MS%9>&S"#.&/W,NHQNR<\!<\'O/_ .BI@GHAX&,$W;'8%& P$_7@6VQ$L=N((
M7]D\L*4/<+/=J[.3TSV+R9")GWUA1\)AD<)-^JZ(!!-^H%S7 Y 9[(U01CT9
M.-M;_V@R(G!(R,+1_L42$)809QE[%8#O;"'O ".? )_L-N#V#W8F0OBB1O_N
MI]NS/?8YX/ ,H*3]0 CZLWA39)^4<HB+SX*X"TCW@*)A%"3/G9WL$:DT7>E'
MPBW2BI -:,V0L3\@(Q^B7X&]:;Q?\P#$0CB2@R0 "\M0H(AD:+"]M7M]=3:@
M ILS$>R>=)U &%$+1 1H;[M EV4A?SGJ&[%^$N*!_ROV!:N6+))J6$IK]8PZ
M#[0ZW]YZ5VX4&\R3KHOH1,W$PY[%[GO2[CW6)_U W4E'L"#V[_D#?!D^0UR'
MVB8,*Y/Z,I3)0O'Z[SB,9.>![,FULG_< 9*$Q;Z<6>PD[L(?6;FJ,<S0T(#-
MK)3+A]M;3]K0W:]_WYRS$P_^;'/8X/;;]_\'6ILS!^0D"&5' IX3LU$ K=$5
MI,.Y_\ <<2=<U9=^EVDK(>((UW1(BC1]B.>!@+Z-EAE%)A N1^(Y6N9")#!(
M(R<FZ8&59K$/&HKY0CA@OI0#9-6L 0]U4M,=:-.="M<C@@O?@:\_XCG<WC ,
M:%4.!PE@78"&Q7T'_BG.C6J3N8.&FH=L]EV P)72X5\@ ,+C@$D0F(C,R1.V
MEM22<0U4'&C7 %RFMG$)8(FLE0<;SIPX,"36)CK%,:(3]2AL HLX6I/AUT !
M$N<U#Y$9;!FB' - 752E#&P;_J*5HT4D)^<,-MG>PL?CH(N@(@,0O#X@0_51
MMX8#E@)0<''NN \)*UF$C?(A"[ETV$T$[.FSDR*[Z7'7M0,5 AI/>U)TV/E/
M80.OW@GVK=.1ME80(QJI"#&$0? W0!6<T@'\VLI]0-S<R2 &^?GV?0]YR@$G
M"-G<D<A(5J+Z <;8E__$ J%,Q +/9*L"'S8;HRX7K+8/7Y6>%_O)AX A!?3L
MH4"Q*/;@[]RV11@:^P1&C"/VM*<K7&E##,%9'V4YC!"M0 *I'Z2%D7/"/J!6
M%!$#<,"N0G)K)DFX I3N'7=C'M&?GO$9@7%\AP=.074*-C)']D06ZPH/ .+P
MC-CW>;O0YZ!;(OY3N""= #,(> !*#/2-8 D:Z,"\[=(G3/# E0*^TP=Z2OAT
M>RN&0X_R;9&!5+A*_4!\WP-(N% [!JN+9XC[2GN=*"0"+ U\EGK'0$* )%">
M\9S+<*S8@5WA"6"]&'1+$(+R@ \T+A)NW][R0"E)$ CF*: WLA6W"3ND>Q12
M !$*H"C0K["Y  $ HQ_0QC9RJO"[\"0/%.S#P@>@F@='^O:=#3-,D7T4#ZCR
M\+!@'?$HL+@? Y[4]E8_#D+X4?51<P(/1BGX'O\I/?D?820Z5=P9\-+  'A"
MZ:= H=(F2%/Q$X@X<(FT6,,SZ# -1!OQK@5Z8L>':'8/-BU[%DTT9&(X24>!
M4X#+I,""9$D/M3H:G,QI,JP)= 'FZH/6PB=1[;4#!?YNP B9HDM,QAT *PPS
MYD=;%T>BC@"Z/K9G81%</T?J(--](/3T."B5B/^ \P'A^J2P.G& @+$D'@7<
M@_DA,.+ 3QP;.C:LH^Y93(^!H0"D$[CH "4N3AL5 P)K-AY2QVU2U?"\[:H0
M/C/>D+$$"1\2?\-!'!5' $B'OI,5^*+1I$NPAW-WBX[^/$8W'YCM*E# FM[C
M\/\$V,:6?4ZAU1?I@C)1O@C?'^W_>3S7Z'SNAR9_6@O7^[EZLHL*Q?1_BW7I
M&WI)4)VX4J%4K,"GL.^G;U]OL[L4.AP\_X?W[.;!:RL7<.A)QU$1 (9??>:!
M%Q)W^GB3_Q<SA,<3ICG>:[[1 *X"\E[ Q:-LU##<MR<?+\_9Z?GEY=7)V=G%
MU\\?=DH[]/O-U<EI\OM?%V>W?WS8*9=*O^W,>E"3 >U'HSG0?@10WEXG*X.M
MC"@",0(/#V(J]@A<2?.->^E$/7BPV-2HV;\].Q[W9XTY]?CO8[7)F0I1G9(3
M!]8"M2]Y59G450B&@I/2S>C8K).-JA7LHZ/0Y(()1<.&C^//Y"SHN!&\\;[P
M"RYO"W>0KR-E3!HZ\2>G=;G8[M,NU]Z3+A=L TXW>=:\ZRMT[@?>U?86A06@
M0"4ZFMIM3*('-%G:>A&26*MB/$?TWY)'P"=";YR%X$6$2?J/$BN(WIL^!#(Z
M6'LY>4A>Z&AH8I*'14WF_=MK_ _R]=AT]C.9^.?SX,^E\)-'_E4HL$]2N,Y[
M=@6N^2&( ,0#X#^ I+!"P10JCLXNOH];NUP9(QT-_*RM N#)]+./+D9]91"]
M$%PD!P 8S=FC4 T.=+0/>X[9O@T*[T>A+8"+ <8^P9P%J3$&(@1SVBTSB-E'
MS&AD+(DZ+U5#*E-40R8',%>MB6J]35.I9R<Z@,!LN,X,4*"=!F-I4/V<#LPH
M.5(<PXH.%S4Q L;J773SX=%")Q 0/H9Q< =QOTL/8E0&3CA+/X3=4K5%6TV2
M/2^R;X_7,;FG9&^&>V?^&@@=*O4#"?32=N:'>#!I+?P$%&L?(O,HI( ==**\
MPZR"47^/PG:,5Q\@0E2#C PM>?[E!+80=U+%(3R<(%X%_1X$%4X0=[>WG$PA
M8BB8&X[C*,9>F'[=5(?S>B@>SOW*-ZG\KI/<-::84#RE?P=1J.SR"*2,LG%@
M>YTT^Z2=JTP&CA+>O",BK2@PQ70GX1<02] 0 8=?0%3=C,;LI[6N1)MM;YD$
M3"> YU7P\"@7P^X%^)(.N%N!)TTVORTP[28I<VJ2/Z1IV!?E2TQB 6RGRO-D
M% E1Q+*:'9.Z,[H3-1H6#%"UH)87 8*A M<!/ I* =X+3(.$27:H&[N<@,.L
MIBV1U.CB)NH.8((#H-;'-,FC Z0F),GRS%U=Y2S]K#U/\H$O&/0TK3;*I..3
MA+?&HO4PJY=:L^VM,>:,C;=F9#4EQAX.P$3IU)PW,L0O)Y;@>=YXVE#\!=*)
MB?80\ (^S,":3L),,]N?BP[+5I0O,;@&#7K2[[N&S"_6Y8=Y#<)+"/XA2O>
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M.^(>@A/)ME0D"<GI<5*/X^G0\(!8XNS8[N>+/1H8CO0PO0Y"/&D##T@T2@[
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M?_QV]O<Q_O#'[9?+X_\/4$L! A0#%     @ KD -6?SMD+DN P  _@L  !
M             ( !     '-Y;BTR,#(T,#@Q,RYX<V102P$"% ,4    " "N
M0 U9E8SM0_T*  " A@  %               @ %< P  <WEN+3(P,C0P.#$S
M7VQA8BYX;6Q02P$"% ,4    " "N0 U9 6XF*UT'  #H5P  %
M    @ &+#@  <WEN+3(P,C0P.#$S7W!R92YX;6Q02P$"% ,4    " "N0 U9
MRS+TR?,2  #S:@  $@              @ $:%@  =&TR-#(Q,S$T9#%?.&LN
M:'1M4$L! A0#%     @ KD -6?<1D_P2)@  >I8! !8              ( !
M/2D  '1M,C0R,3,Q-&0Q7V5X.3DM,2YH=&U02P4&      4 !0!& 0  @T\
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>tm2421314d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="syn-20240813.xsd" xlink:type="simple"/>
    <context id="AsOf2024-08-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <startDate>2024-08-13</startDate>
            <endDate>2024-08-13</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-08-13" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-08-13" id="Fact000004">0000894158</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-08-13" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-08-13" id="Fact000010">2024-08-13</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-08-13" id="Fact000011">THERIVA BIOLOGICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-08-13" id="Fact000012">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-08-13" id="Fact000013">001-12584</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-08-13" id="Fact000014">13-3808303</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-08-13" id="Fact000015">9605 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2024-08-13" id="Fact000016">Suite 270</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-08-13" id="Fact000017">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-08-13" id="Fact000018">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-08-13" id="Fact000019">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-08-13" id="Fact000020">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-08-13" id="Fact000021">417-4364</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-08-13" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-08-13" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-08-13" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-08-13" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2024-08-13" id="Fact000026">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-08-13" id="Fact000027">TOVX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-08-13" id="Fact000028">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-08-13" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
